The U.S. Food and Drug Administration (FDA) has granted 510(k) approval to GE HealthCare's MIM Software for its Monte Carlo dosimetry approach, which allows radionuclide absorbed dose estimations using the Dose Planning approach (DPM), the company stated on October 3, 2024. This clearance allows for the integration of advanced dosimetry capabilities into MIM SurePlan MRT, a comprehensive solution designed to automate and standardize dosimetry in Theranostics, a personalized medicine approach that tailors treatment to individual patient needs.
The Monte Carlo method is recognized as the “gold standard” for radiopharmaceutical therapy dosimetry, delivering high calculation accuracy in tissues with heterogeneous densities. The DPM technique, developed by the University of Michigan, simulates photon and electron interactions to enhance treatment personalization. MIM SurePlan MRT automates various dosimetry processes, significantly reducing calculation time from hours to mere seconds using existing hardware without the need for additional graphics processing units. This innovation aims to improve access to precise and personalized cancer treatment options, reinforcing GE HealthCare’s commitment to enhancing patient outcomes through advanced Theranostics solutions.
